Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Venlafaxine
|
| gptkbp:activities |
inhibits reuptake of serotonin and norepinephrine
|
| gptkbp:affects |
possible heart rate increase
possible increased cholesterol possible liver function changes possible weight gain |
| gptkbp:approves |
gptkb:2008
gptkb:FDA |
| gptkbp:brand |
gptkb:Pristiq
|
| gptkbp:category |
gptkb:C
|
| gptkbp:class |
serotonin-norepinephrine reuptake inhibitor (SNRI)
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
MAO inhibitors
severe renal impairment |
| gptkbp:developed_by |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:dosage_form |
100 mg once daily
50 mg once daily |
| gptkbp:form |
oral solution
extended-release tablet |
| gptkbp:has_ability |
100 mg
50 mg 150 mg 25 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
desvenlafaxine
|
| gptkbp:ingredients |
C16 H25 N
|
| gptkbp:interacts_with |
gptkb:beer
anticoagulants other antidepressants |
| gptkbp:is_atype_of |
N06 A X16
|
| gptkbp:is_used_for |
major depressive disorder
|
| gptkbp:lifespan |
11 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
depression treatment
chronic pain management anxiety treatment neuropathic pain treatment fibromyalgia treatment |
| gptkbp:side_effect |
anxiety
dizziness nausea insomnia constipation dry mouth sweating sexual dysfunction increased blood pressure |
| gptkbp:symptoms |
dizziness
fatigue nausea irritability |
| gptkbp:traded_on |
Khedezla
|